Assembly Biosciences
Manufacturing · California, United States · 51-200 Employees
View Company Info for Free
Overview
Headquarters
Two Tower Pl Fl 7, South San Francisco, ...Phone Number
(833) 509-4583Website
www.assemblybio.comRevenue
$71.1 MillionStock Symbol
ASMBIndustry
ZI Rank: 1
Signal Type
Dec
Jan
Feb
Mar
Apr
May
ZI Rank
3
2
1
1
1
1
About Assembly Biosciences
Assembly Biosciences, Inc., a clinical stage biotechnology company, develops oral therapeutics for the treatment of hepatitis B virus (HBV) infection and novel class of oral synthetic live biotherapeutics to restore health to a dysbiotic microbiome in the United States.Explore more
Assembly Biosciences Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Assembly Biosciences your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Website visits: Recent activity has been detected on your website
Earning: See what the market has to say on Assembly Biosciences recently announced quarterly report
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Check if Assembly Biosciences has recently received funding, and reach out quickly before it becomes old news!
Click to see if Assembly Biosciences had a recent Job posting/layoffs
Assembly Biosciences, which may be a good buyer, showed buying intent in Masked Content Topic
Funding: Get notified immidiatlly once Assembly Biosciences has new funding data
Product Launch: Get notified when Assembly Biosciences launches new products
Congratulate Masked Content for being promoted to Masked Content at Assembly Biosciences
Check out if Assembly Biosciences is spiking on competitors!
Recommended Actions
Introduce yourself to Masked Content, who has shown a strong intent to purchase lately
Find 3 more new buyers
Compare Similar Companies to Assembly Biosciences
Compare insights from companies similar to Assembly Biosciences, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Company Profile Activity
Activity Insights
Assembly Biosciences is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
Assembly Biosciences is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about Assembly Biosciences.
Assembly Biosciences financials insights
Gather financial insights about Assembly Biosciences, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2010
Multiple Rounds
$20.8M
2024
Private Equity
$12.6M
Private Equity
$30M
Assembly Biosciences Tech Stack
A closer look at the technologies used by Assembly Biosciences
See more technologies
Most Recent Scoops
Person-Based
Pharmaceuticals
Person-Based
Medical Research
Project
Laboratory Operations, Medical Research, Clinical Operations
Open Position
Person-Based
Assembly Biosciences News & Media
Assembly Biosciences Announces Upcoming Investor Conference Presentations
SOUTH SAN FRANCISCO, Calif., May 28, 2026 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (Nasdaq: ASMB), a biotechnology company developing innovative therapeutics targeting serious viral and liver diseases, today announced senior management will participate in fireside chats at two upcoming investor conferences:Assembly Biosciences Announces the Closing of its Offering of Common Stock and Pre-Funded Warrants and Full Exercise of the Underwriters’ Option to Purchase Additional Shares
SOUTH SAN FRANCISCO, Calif., May 26, 2026 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (Nasdaq: ASMB), a biotechnology company developing innovative therapeutics targeting serious viral and liver diseases, today announced the closing of its previously announced underwritten registered offering of 3,924,624 shares of its common stock at an offering price per share of common stock of $26.50, which includes the exercise in full by the underwriters of their option to purchase 566,040 additional shAssembly Biosciences Announces Pricing of $100 Million Offering of Common Stock and Pre-Funded Warrants
SOUTH SAN FRANCISCO, Calif., May 22, 2026 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (Nasdaq: ASMB), a biotechnology company developing innovative therapeutics targeting serious viral and liver diseases, today announced the pricing of an underwritten, registered offering (the offering) of an aggregate of 3,358,602 shares of common stock at an offering price per share of common stock of $26.50, and, to certain investors in lieu of common stock, pre-funded warrants to purchase up to 415,000 shAssembly Biosciences Announces Expansion of ABI-6250 Clinical Development Into Cholestatic Liver Diseases
– Phase 2 study in cholestatic liver diseases, focused on PBC and PSC, anticipated to initiate in Q1 2027 – – Builds on completed Phase 1a study and ongoing development in HDV –
Read more news
Top Manufacturing Companies
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding Assembly Biosciences
Sign Up For FreeTo access detailed company insights
Assembly Biosciences, Inc., a clinical stage biotechnology company, develops oral therapeutics for the treatment of hepatitis B virus (HBV) infection and novel class of oral synthetic live biotherapeutics to restore health to a dysbiotic microbiome in the United States.... Read More
